We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LDL Subclasses Ratio Predicts Cardiovascular Disease Risk More Accurately than LDL-cholesterol Alone

By LabMedica International staff writers
Posted on 27 Nov 2019
Print article
Image: Small particle LDL has been associated with the progression of atherosclerosis and blockage the artery lumen, because it can carry cholesterol into smaller vessels. As atheroma enlarges, the arterial wall ruptures and releases blood clots that lead to narrowing of the artery (Photo courtesy of Wikimedia Commons)
Image: Small particle LDL has been associated with the progression of atherosclerosis and blockage the artery lumen, because it can carry cholesterol into smaller vessels. As atheroma enlarges, the arterial wall ruptures and releases blood clots that lead to narrowing of the artery (Photo courtesy of Wikimedia Commons)
Measurement of low-density lipoprotein (LDL) cholesterol may a less effective way to predict risk of cardiovascular disease than is the further analysis of the relative proportions of LDL subclasses.

About 75% of patients with heart attacks have cholesterol levels, particularly LDL-cholesterol levels - that do not indicate a high risk for a cardiovascular event. LDL comprises a diverse group of macromolecules that may be grouped according to size: large low density LDL particles are described as subclass A, and small high density LDL particles are subclass B. Subclass B has been associated by some with a higher risk for coronary heart disease. This is thought to be because the smaller particles are more easily able to penetrate the endothelium of arterial walls. Subclass I, for intermediate, indicates that most LDL particles are very close in size to the normal gaps in the endothelium.

A recent study carried out at Ohio University (Athens, USA) suggested that contrary to the current [U.S.] national guidelines it was not the total LDL, rather it was the concentration of subclass B in relation to subclasses A and/or I, that should be used for diagnosis of atherosclerosis and the risk of heart attack.

The investigators reached this conclusion after utilizing a nanomedical approach. They used nanosensors with a diameter of less than 300 nanometers, to simultaneously measure, in near-real time, the concentration of cytoprotective nitric oxide (NO) and cytotoxic peroxynitrite (ONOO−) released from a single endothelial cell exposed to each of the LDL subclasses (A, B, and I). The ratio of NO concentration to ONOO− concentration (NO)/(ONOO−) was used as a marker of oxidative stress and the dysfunction of the enzyme endothelial nitric oxide synthase (eNOS).

Results revealed that all n-LDL (native LDL) and ox-LDL (oxidized LDL) subclasses unfavorably shifted the balance of the (NO)/(ONOO−) ratio, imposing toxic effects such as: elevated oxidative stress, a shortage of cytoprotective NO, and the up-regulation of adhesion molecules in the endothelium. However, subclass B dramatically shifted (NO)/(ONOO−) balance to a very low level, causing significant damage to endothelial function.

"Our studies can explain why a correlation of total "bad" cholesterol with a risk of heart attack is poor and dangerously misleading – it is wrong three quarters of the time," said senior author Dr. Tadeusz Malinski, professor of chemistry and biochemistry at Ohio University. "These national guidelines may seriously underestimate the noxious effects of LDL cholesterol, especially in cases where the content of subclass B in total LDL is high (50% or higher). Understanding this could lead to improving the accuracy of diagnosis for the evaluation of cardiovascular disease rates. Analyzing the mixture of LDL subclasses may provide a parameter-based model for an early medical diagnosis of estimating the risk of cardiovascular disease."

The study was published in the November 18, 2019, issue of the International Journal of Nanomedicine.

Related Links:
Ohio University

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Pipet Controller
Stripettor Pro
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more